NOVEMBER 2024 I MAZE THERAPEUTICS

About Us
our approach
- overview
- publications
our pipeline
investors
Careers

About Us
our approach
- overview
- publications
our pipeline
investors
Careers

NOVEMBER 2024 I MAZE THERAPEUTICS

Clinical Pharmacology & Therapeutics | Ullman et al.

First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease

back to press

info@mazetx.com 171 Oyster Point Blvd, Suite 300 South San Francisco, CA 94080 (650) 850-5070

Maze 2026©

About Us
our approach
our pipeline
publications
Careers
investors
Contact
Privacy Notice
Terms of Use

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Essential Cookies

These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.

Enable or Disable Cookies Enabled Disabled

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies Enabled Disabled